Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
Publication/Presentation Date
1-1-2007
Abstract
Steroid refractory graft versus host disease (GVHD) presents a significant therapeutic challenge due to the limited efficacy and safety of second-line treatments. Three patients with extensively pretreated, refractory GVHD were treated with a targeted anti-T-cell agent, alefacept, and demonstrated rapid and clinically significant improvement in their GVHD, facilitating tapering of corticosteroids. The pathological and immunohistochemical findings of GVHD also improved, validating our clinical impression. These preliminary findings indicate that alefacept may have beneficial activity in GVHD warranting further study.
Volume
18
Issue
1
First Page
13
Last Page
18
ISSN
0954-6634
Published In/Presented At
Toor, A. A., Stiff, P. J., Nickoloff, B. J., Rodriguez, T., Klein, J. L., & Gordon, K. B. (2007). Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. The Journal of dermatological treatment, 18(1), 13–18. https://doi.org/10.1080/09546630601121045
Disciplines
Medicine and Health Sciences
PubMedID
17365261
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article